Abstract
Purpose: Incorporation of brachytherapy (BT) into the radiation management of prostate cancer has been guided by the use of risk stratification derived for external beam (EBRT) treatment. This raises questions about the appropriateness of EBRT risk groups for BT of prostate cancer. The purpose of this work was to derive risk groups for low dose rate (LDR) monotherapy of prostate cancer, compare them with those used for EBRT, and test for significant differences in clinical failure-free survival (CFFs) between patients in the same EBRT risk group.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
